Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial

Authors: Jonathan D. Schoenfeld, Anita Giobbie‐Hurder, Srinika Ranasinghe, Katrina Kao, Ana Lako, Junko Tsuji, Yang Liu, Ryan Brennick, Ryan D. Gentzler, Carrie B. Lee, Joleen M. Hubbard, Susanne M. Arnold, James L. Abbruzzese, Salma K. Jabbour, Nataliya V. Uboha, Kevin L. Stephans, Jennifer M. Johnson, Haeseong Park, Liza C. Villaruz, Elad Sharon, Howard Streicher, Mansoor M. Ahmed, Hayley Lyon, Carrie Cibuskis, Niall J. Lennon, Aashna Jhaveri, Lin Yang, Jennifer Altreuter, Lauren Gunasti, Jason L. Weirather, Raymond H. Mak, Mark M. Awad, Scott J. Rodig, Helen X Chen, Catherine J. Wu, Arta M. Monjazeb, F. Stephen Hodi - The Lancet 2022 cited by 232